Status:
UNKNOWN
Anticoagulant-associated Intracranial Hemorrhage
Lead Sponsor:
El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez
Collaborating Sponsors:
AstraZeneca
Conditions:
Anticoagulant-induced Bleeding
Intracranial Hemorrhages
Eligibility:
All Genders
Brief Summary
Oral anticoagulant therapy, including factors Xa and 2a inhibitors has become more popular in recent years due to its efficacy and convenience in preventing thrombotic events and reducing the risk for...
Detailed Description
Study observational. The total number of subjects for this study will be determined by the number of patients with intracranial bleeding associated with anticoagulant therapy on the clinical records. ...
Eligibility Criteria
Inclusion
- Age \>18 years
- Intracranial hemorrhage diagnosis and concomitant oral anticoagulant therapy
- Available clinical record from January 2015 to July 2023
Exclusion
- Non available clinical record
- Patients that did not complete follow up on days 30 and 90 after an intracranial bleeding.
Key Trial Info
Start Date :
August 9 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 31 2024
Estimated Enrollment :
1200 Patients enrolled
Trial Details
Trial ID
NCT06168838
Start Date
August 9 2023
End Date
January 31 2024
Last Update
December 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto Nacional de Neurología y Neurocirugía
Mexico City, Mexico, 14269